Syndax Pharmaceuticals (SNDX) opened Q1 2026 with total revenue of US$64.9 million and a basic EPS loss of US$0.48, alongside a net loss of US$42.7 million. This puts fresh numbers around how the business is scaling its commercial model while still running in the red. Over recent quarters the company has reported revenue of US$7.7 million in Q4 2024, US$20.0 million in Q1 2025, and US$68.7 million in Q4 2025, with basic EPS losses of US$1.10, US$0.98, and US$0.78 over those same periods as it continued to invest ahead of profitability. The latest results keep attention on how quickly margins may move toward break even.

See our full analysis for Syndax Pharmaceuticals.

With the numbers on the table, the next step is to see how this earnings profile lines up with the widely followed Syndax narratives, and where the latest results might encourage investors to reassess the story.

Loss narrows to US$42.7 million on a much larger revenue base

• Net income loss in Q1 2026 was US$42.7 million on US$64.9 million of revenue, compared with a loss of US$68.0 million on US$68.7 million of revenue in Q4 2025 and US$94.2 million on US$7.7 million of revenue in Q4 2024.
• Consensus narrative expects expanding drug adoption and operating leverage to support future margins, and the recent shift from a trailing 12 month loss of US$285.4 million in Q4 2025 to US$243.2 million in Q1 2026 shows how a larger revenue base can start to compress losses, even though the company is still firmly in the red.
  • Analysts in that balanced view see profit margin moving from about a 165.6% loss today to a 14.7% profit margin in three years, while the latest quarter still reports a basic EPS loss of US$0.48.
  • This gap between current negative earnings and a forecast profit of US$110.2 million highlights how much of the consensus story depends on revenue growth translating into sustained cost discipline.

Trailing 12 month loss of US$243.2 million keeps profitability in focus

• On a trailing 12 month basis, revenue stands at US$217.2 million with a net loss of US$243.2 million and basic EPS of US$2.79 loss, and over the past five years reported losses have grown at about 37.3% per year.
• Bears argue that heavy dependence on a few lead drugs and high R&D and SG&A costs could keep losses elevated, and the current trailing 12 month loss and negative EPS give that cautious view some numerical backing even as quarterly losses have recently been smaller than the five year trend might suggest.
  • The bearish narrative points to the need for revenues above the US$217.2 million trailing level to support long term investment, while the history of multi year loss growth shows the company has been willing to spend heavily to build the business.
  • Critics also highlight that analysts expecting US$81.2 million of earnings in a bearish earnings scenario still require a large swing from the current US$243.2 million loss, which leaves little room for disappointment in trial outcomes or commercialization progress.

On this kind of loss profile, it helps to see how skeptics think the story could stall before profitability, and where they think the biggest earnings risks sit under different revenue paths. 🐻 Syndax Pharmaceuticals Bear Case

P/S of 7.8x and DCF fair value of US$81.89 frame the upside debate

• The stock trades at a P/S of 7.8x on the provided numbers, below the cited US biotechs average of 11x and peer average of 12x, while the DCF fair value in the dataset is US$81.89 against a current share price of US$19.11.
• Bullish investors argue that strong forecast growth, including revenue growth of about 31% per year and earnings growth of roughly 60.5% per year, could help close the gap between the current share price, the US$39.50 analyst price target and the DCF fair value, but the trailing 12 month loss of US$243.2 million shows that a lot of execution still needs to happen.
  • Supporters point to the step up in quarterly revenue from US$7.7 million in Q4 2024 to US$64.9 million in Q1 2026 as a sign that the commercial model is gaining scale, which they see as important if the P/S discount to peers is going to narrow over time.
  • At the same time, the stock already prices in some of that optimism, as the analyst target of US$39.50 implies a premium to today’s US$19.11 level and still sits well below the US$81.89 DCF fair value, which keeps attention on whether future quarters can support the higher earnings and margin assumptions in the bullish scenarios.

If you want to see how optimistic investors connect these valuation gaps to the high growth forecasts, and what milestones they are watching most closely, 🐂 Syndax Pharmaceuticals Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Syndax Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Reading through the bull and bear cases, do the risks or the rewards stand out more to you right now? Act while the details are fresh and pressure test your own view by weighing the 2 key rewards and 1 important warning sign

See What Else Is Out There

Syndax still carries a trailing 12 month net loss of US$243.2 million and basic EPS loss, so profitability and earnings quality remain key pressure points.

If that level of ongoing losses and earnings volatility makes you uneasy, it is worth comparing alternatives with stronger downside protection using the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.